Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea

Dae Hee Kim, Il Young Oh, Hae Young Lee, Yong Jin Kim, Hyo Soo Kim, Cheol Ho Kim, Byung Hee Oh, Kwon Sam Kim, Doo Il Kim, Young Dae Kim, Kyu Hyung Ryu, Si Hoon Park, Sang Hong Baek, Dong Gu Shin, Wan Joo Shim, Tae Hoon Ahn, Seok Kyu Oh, Seung Hwan Lee, Sung Yun Lee, Myung Ho JeongWook Sung Chung, Jun Young Jeong, So Yeon Choi, Si Wan Choi, Min Su Hyon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalKorean Circulation Journal
Volume40
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, D. H., Oh, I. Y., Lee, H. Y., Kim, Y. J., Kim, H. S., Kim, C. H., Oh, B. H., Kim, K. S., Kim, D. I., Kim, Y. D., Ryu, K. H., Park, S. H., Baek, S. H., Shin, D. G., Shim, W. J., Ahn, T. H., Oh, S. K., Lee, S. H., Lee, S. Y., ... Hyon, M. S. (2010). Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea. Korean Circulation Journal, 40(12), 632-638. https://doi.org/10.4070/kcj.2010.40.12.632